drugset / Trial / NCT00782600

Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers

NCT00782600

Phase 1 Completed 16 enrolled Pfizer
RandomizedCrossoverOpen-labelTreatment

Summary

This study is to test the idea that a controlled release formulation of CE-224,535 may allow for less frequent dosing and exposure to lower levels of drug than an immediate release formulation.

Timeline

Start
2008-07
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CE-224,535 Small molecule 50 mg Oral

Indications